JP2011525477A5 - - Google Patents

Download PDF

Info

Publication number
JP2011525477A5
JP2011525477A5 JP2010549861A JP2010549861A JP2011525477A5 JP 2011525477 A5 JP2011525477 A5 JP 2011525477A5 JP 2010549861 A JP2010549861 A JP 2010549861A JP 2010549861 A JP2010549861 A JP 2010549861A JP 2011525477 A5 JP2011525477 A5 JP 2011525477A5
Authority
JP
Japan
Prior art keywords
vaccine composition
particles
aspect ratio
antigen
immunostimulatory agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010549861A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011525477A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/036068 external-priority patent/WO2009111588A1/en
Publication of JP2011525477A publication Critical patent/JP2011525477A/ja
Publication of JP2011525477A5 publication Critical patent/JP2011525477A5/ja
Pending legal-status Critical Current

Links

JP2010549861A 2008-03-04 2009-03-04 免疫調節剤粒子および処置方法 Pending JP2011525477A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6822708P 2008-03-04 2008-03-04
US61/068,227 2008-03-04
PCT/US2009/036068 WO2009111588A1 (en) 2008-03-04 2009-03-04 Immunomodulator particles and methods of treating

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014238952A Division JP2015078204A (ja) 2008-03-04 2014-11-26 免疫調節剤粒子および処置方法

Publications (2)

Publication Number Publication Date
JP2011525477A JP2011525477A (ja) 2011-09-22
JP2011525477A5 true JP2011525477A5 (https=) 2012-04-26

Family

ID=41056361

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010549861A Pending JP2011525477A (ja) 2008-03-04 2009-03-04 免疫調節剤粒子および処置方法
JP2014238952A Pending JP2015078204A (ja) 2008-03-04 2014-11-26 免疫調節剤粒子および処置方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014238952A Pending JP2015078204A (ja) 2008-03-04 2014-11-26 免疫調節剤粒子および処置方法

Country Status (5)

Country Link
US (2) US20110151015A1 (https=)
EP (1) EP2262480B1 (https=)
JP (2) JP2011525477A (https=)
CN (1) CN102014874A (https=)
WO (1) WO2009111588A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100055459A1 (en) * 2006-08-30 2010-03-04 Liquidia Technologies, Inc. Nanoparticles Having Functional Additives for Self and Directed Assembly and Methods of Fabricating Same
WO2008127455A2 (en) * 2006-12-05 2008-10-23 Liquidia Technologies, Inc. Nanoarrays and methods and materials for fabricating same
AU2008222678B2 (en) 2007-03-07 2013-01-17 The General Hospital Corporation Compositions and methods for the prevention and treatment of autoimmune conditions
CA2762653A1 (en) 2009-05-27 2010-12-02 Selecta Biosciences, Inc. Immunomodulatory agent-polymeric compounds
CN102834112B (zh) * 2010-02-22 2016-02-24 流体科技公司 多糖颗粒疫苗
AU2011258165B2 (en) 2010-05-26 2016-11-17 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
US20130203675A1 (en) 2010-09-16 2013-08-08 Joseph M. DeSimone Asymmetric biofunctional silyl monomers and particles thereof as prodrugs and delivery vehicles for pharmaceutical, chemical and biological agents
WO2012061717A1 (en) 2010-11-05 2012-05-10 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
KR20140041505A (ko) 2011-04-29 2014-04-04 셀렉타 바이오사이언시즈, 인크. 조절 b 세포 유도를 위한 관용원성 합성 나노운반체
JP2014521687A (ja) 2011-07-29 2014-08-28 セレクタ バイオサイエンシーズ インコーポレーテッド 体液性および細胞傷害性ｔリンパ球（ｃｔｌ）免疫応答を生成する合成ナノキャリア
US20150037428A1 (en) 2011-11-29 2015-02-05 The University Of North Carolina At Chapel Hill Geometrically engineered particles and methods for modulating macrophage or immune responses
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
WO2014165728A1 (en) * 2013-04-05 2014-10-09 The University Of North Carolina At Chapel Hill Particles having peg-ylated surfaces modified for lymphatic trafficking
SG10201803780UA (en) 2013-11-04 2018-06-28 Uti Lp Methods and compositions for sustained immunotherapy
ES3055030T3 (en) 2015-05-06 2026-02-09 Uti Lp Nanoparticle compositions for sustained therapy
JP2019513128A (ja) 2016-03-07 2019-05-23 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 薬物送達粒子
US10898494B2 (en) 2016-05-05 2021-01-26 Liquidia Technologies, Inc. Dry powder treprostinil for the treatment of pulmonary hypertension
EP3716949A4 (en) 2017-11-29 2022-05-18 UTI Limited Partnership Methods of treating autoimmune disease
WO2021212037A1 (en) * 2020-04-16 2021-10-21 Emory University Immune cell redirecting compositions and therapeutic uses thereof
CN116407624B (zh) * 2023-04-14 2024-04-09 吉林省农业科学院(中国农业科技东北创新中心) 一种鸡传染性支气管炎细菌样颗粒疫苗的制备方法和应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090406A (en) * 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5709879A (en) 1990-06-29 1998-01-20 Chiron Corporation Vaccine compositions containing liposomes
GB9227068D0 (en) * 1992-12-29 1993-02-24 British Bio Technology Novel proteinaceous particles
FR2723849B1 (fr) 1994-08-31 1997-04-11 Biovector Therapeutics Sa Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique
US5686113A (en) * 1995-03-21 1997-11-11 Temple University Of The Commonwealth System Of Higher Education Microcapsules of predetermined peptide(s) specificity (ies), their preparation and uses
ES2175668T3 (es) * 1997-12-16 2002-11-16 Chiron Corp Uso de microparticulas combinadas con emulsiones de aceite en agua submicronicas.
US6086881A (en) * 1998-05-15 2000-07-11 Children's Medical Center Corp. Spatially aligned conjugated composition having a thioether bond linkage
DE69940353D1 (en) * 1998-11-11 2009-03-12 Univ Oklahoma Polymerpfropfung mittels polysaccharide-synthase
US6326021B1 (en) * 1999-06-18 2001-12-04 The Ohio State University Research Foundation Biocompatible polymeric delivery systems having functional groups attached to the surface thereof
US7060284B1 (en) 1999-08-03 2006-06-13 The Ohio State University Polypeptides and polynucleotides for enhancing immune reactivity to HER-2 protein
US20020061312A1 (en) * 2000-07-31 2002-05-23 Ruslan Medzhitov Innate immune system-directed vaccines
US20030232055A1 (en) 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
US20030175287A1 (en) 2001-01-03 2003-09-18 Yale University Innate immune system-directed vaccines
CA2446458A1 (en) 2001-05-09 2002-11-14 Yale University Toll/interleukin-1 receptor adaptor protein (tirap)
AU2003205071A1 (en) * 2002-01-09 2003-07-30 Yale University Irak-m is a negative regulator of toll-like receptor signaling
WO2003059285A2 (en) * 2002-01-09 2003-07-24 Yale University Rip2: a method of signaling in the innate and adaptive immune systems
CA2481980A1 (en) * 2002-04-05 2003-10-23 Progenics Pharmaceuticals, Inc. Particle-bound human immunodeficiency virus envelope glycoproteins and related compositions and methods
WO2003089602A2 (en) * 2002-04-19 2003-10-30 Yale University Toll-like receptor 11 and toll-like receptor 12
US20040009943A1 (en) * 2002-05-10 2004-01-15 Inex Pharmaceuticals Corporation Pathogen vaccines and methods for using the same
US7393493B2 (en) * 2003-02-27 2008-07-01 A Enterprises, Inc. Crosslinkable polymeric materials and their applications
WO2005030133A2 (en) 2003-09-22 2005-04-07 Yale University Treatment with agonists of toll-like receptors
US20050118199A1 (en) * 2003-10-07 2005-06-02 Esser Mark T. Process for covalently conjugating polysaccharides to microspheres or biomolecules
US20070275007A1 (en) * 2003-11-05 2007-11-29 The Government Of The United States Of America, Represented By The Secretary Of Health And Human S Carbohydrate Antigen-Nanoparticle Conjugates and Uses Thereof as Antimetastatic Agents in Treating Cancer
DK1704585T3 (en) * 2003-12-19 2017-05-22 Univ North Carolina Chapel Hill Methods for preparing isolated micro- and nanostructures using soft lithography or printing lithography
US9040090B2 (en) * 2003-12-19 2015-05-26 The University Of North Carolina At Chapel Hill Isolated and fixed micro and nano structures and methods thereof
WO2005072778A2 (en) * 2004-01-29 2005-08-11 Biosynexus, Inc. Use of amino-oxy functional groups in the preparation of vaccines conjugates
JP2008532929A (ja) * 2005-02-01 2008-08-21 メディバス エルエルシー ワクチン送達組成物および使用法
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
MX2007016039A (es) 2005-06-17 2008-10-27 Univ North Carolina Metodos, sistemas y materiales de fabricacion de nanoparticulas.
EP1951202A4 (en) 2005-11-07 2013-03-06 Univ North Carolina ISOLATED AND SOLID MICRO AND NANO STRUCTURES AND METHOD THEREFOR
WO2007081876A2 (en) * 2006-01-04 2007-07-19 Liquidia Technologies, Inc. Nanostructured surfaces for biomedical/biomaterial applications and processes thereof
US20090220789A1 (en) 2006-01-27 2009-09-03 The University Of North Carolina At Chapel Hill Taggants and methods and systems for fabricating same
AU2007227504B2 (en) * 2006-03-17 2013-10-31 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for preparing complex multivalent immunogenic conjugates
WO2008011051A1 (en) * 2006-07-17 2008-01-24 Liquidia Technologies, Inc. Nanoparticle fabrication methods, systems, and materials
US20100055459A1 (en) * 2006-08-30 2010-03-04 Liquidia Technologies, Inc. Nanoparticles Having Functional Additives for Self and Directed Assembly and Methods of Fabricating Same
NZ575901A (en) * 2006-09-12 2012-04-27 Alphavax Inc Alphavirus replicon particles matched to protein antigens as immunological adjuvants
US20100196277A1 (en) * 2006-10-09 2010-08-05 The University Of North Carolina At Chapel Hill Nanoparticle compositions for controlled delivery of nucleic acids
AU2008241470B2 (en) * 2007-04-16 2013-11-07 Corium Pharma Solutions, Inc. Solvent-cast microneedle arrays containing active

Similar Documents

Publication Publication Date Title
JP2011525477A5 (https=)
Hanif et al. Halloysite nanotubes as a new drug-delivery system: a review
Zhou et al. Biomimetic nanotechnology toward personalized vaccines
Vinay et al. Recent advances in application of nanoparticles in fish vaccine delivery
Meyer et al. Biomimetic particles as therapeutics
Griffiths et al. Nanobead-based interventions for the treatment and prevention of tuberculosis
UY37326A (es) Dispersiones sólidas extruidas por fusión que contienen un agente inductor de apoptosis
Zhang et al. DNA origami as an in vivo drug delivery vehicle for cancer therapy
JP2013530158A5 (https=)
AR093449A1 (es) Polvo farmaceutico compuesto de nucleo-recubrimiento y procedimientos para producirlo
JP2011178784A5 (https=)
JP2015500342A5 (https=)
JP2011037876A5 (https=)
Fawzy et al. Nanoparticles as a novel and promising antiviral platform in veterinary medicine
Leporatti Halloysite clay nanotubes as nano‐bazookas for drug delivery
JP2014533698A5 (https=)
RU2014128590A (ru) Применение полимерных эксципиентов для лиофилизации или заморозки частиц
JP2008505857A5 (https=)
JP2014526519A5 (https=)
Khatua et al. Advances in engineered nanosystems: immunomodulatory interactions for therapeutic applications
Beletskii et al. Engineered PRINT® nanoparticles for controlled delivery of antigens and immunostimulants
Hani et al. Current perspectives on novel drug delivery systems and approaches for management of cervical cancer: a comprehensive review
De Smet et al. Spray-dried polyelectrolyte microparticles in oral antigen delivery: stability, biocompatibility, and cellular uptake
Yin et al. Biodegradable Imiquimod-Loaded Mesoporous Organosilica as a Nanocarrier and Adjuvant for Enhanced and Prolonged Immunity against Foot-and-Mouth Disease Virus in Mice
Zhang et al. Polymer–protein core–shell nanoparticles for enhanced antigen immunogenicity